Drug testing for performance-enhancing drugs could begin this week at the SBS Open in Hawaii, making the LPGA tour the first major golf tour to implement such a program.

In accordance with LPGA rules, players will be subject to unannounced, random "in-competition testing."

That means all testing will take place at tournaments after the completion of any round. Players, however, won't be alerted to which tournaments will be testing sites.

"For the health of the tour, we need to protect the integrity of the tour and it seems like this is what the times are calling for," says Wendy Ward, a tour member since 1996 and a member of the LPGA Player Executive Committee from 2003-05. "We all work hard out here and we need to ensure that everyone is playing on equal ground."